The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo

Treatment with anti-CD20 antibodies is only moderately efficient in chronic lymphocytic leukemia (CLL), a feature which has been explained by the inherently low CD20 expression in CLL. It has been shown that CD20 is epigenetically regulated and that histone deacetylase inhibitors (HDACis) can increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Scialdone, Annarita, Hasni, Muhammad Sharif, Damm, Jesper Kofoed, Lennartsson, Andreas, Gullberg, Urban, Drott, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514918/
https://www.ncbi.nlm.nih.gov/pubmed/28445158
http://dx.doi.org/10.18632/oncotarget.16964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514918/
https://www.ncbi.nlm.nih.gov/pubmed/28445158
http://dx.doi.org/10.18632/oncotarget.16964

Ejemplares similares